WallStSmart

Arm Holdings plc American Depositary Shares (ARM)vsBoston Scientific Corp (BSX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Boston Scientific Corp generates 330% more annual revenue ($20.07B vs $4.67B). ARM leads profitability with a 17.2% profit margin vs 14.4%. BSX appears more attractively valued with a PEG of 0.75. BSX earns a higher WallStSmart Score of 63/100 (C+).

ARM

Buy

52

out of 100

Grade: C-

Growth: 6.0Profit: 7.0Value: 4.7Quality: 7.8
Piotroski: 5/9Altman Z: 3.75

BSX

Buy

63

out of 100

Grade: C+

Growth: 8.0Profit: 6.5Value: 8.7Quality: 5.5
Piotroski: 4/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ARMSignificantly Overvalued (-2323.2%)

Margin of Safety

-2323.2%

Fair Value

$5.17

Current Price

$157.07

$151.90 premium

UndervaluedFair: $5.17Overvalued
BSXUndervalued (+1.2%)

Margin of Safety

+1.2%

Fair Value

$70.62

Current Price

$69.78

$0.84 discount

UndervaluedFair: $70.62Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ARM3 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
3.7510/10

Safe zone — low bankruptcy risk

Market CapQuality
$143.33B9/10

Large-cap with strong market position

Revenue GrowthGrowth
26.3%8/10

Revenue surging 26.3% year-over-year

BSX4 strengths · Avg: 8.3/10
Market CapQuality
$101.28B9/10

Large-cap with strong market position

PEG RatioValuation
0.758/10

Growing faster than its price suggests

Revenue GrowthGrowth
15.9%8/10

15.9% revenue growth

Free Cash FlowQuality
$1.01B8/10

Generating 1.0B in free cash flow

Areas to Watch

ARM4 concerns · Avg: 2.5/10
PEG RatioValuation
1.904/10

Expensive relative to growth rate

P/E RatioValuation
177.6x2/10

Premium valuation, high expectations priced in

Price/BookValuation
21.4x2/10

Trading at 21.4x book value

EPS GrowthGrowth
-12.3%2/10

Earnings declined 12.3%

BSX1 concerns · Avg: 4.0/10
P/E RatioValuation
35.1x4/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : ARM

The strongest argument for ARM centers on Altman Z-Score, Market Cap, Revenue Growth. Profitability is solid with margins at 17.2% and operating margin at 15.4%. Revenue growth of 26.3% demonstrates continued momentum.

Bull Case : BSX

The strongest argument for BSX centers on Market Cap, PEG Ratio, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.

Bear Case : ARM

The primary concerns for ARM are PEG Ratio, P/E Ratio, Price/Book. A P/E of 177.6x leaves little room for execution misses.

Bear Case : BSX

The primary concerns for BSX are P/E Ratio.

Key Dynamics to Monitor

ARM carries more volatility with a beta of 4.13 — expect wider price swings.

ARM is growing revenue faster at 26.3% — sustainability is the question.

BSX generates stronger free cash flow (1.0B), providing more financial flexibility.

Monitor SEMICONDUCTORS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BSX scores higher overall (63/100 vs 52/100) and 15.9% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Arm Holdings plc American Depositary Shares

TECHNOLOGY · SEMICONDUCTORS · USA

Arm Holdings plc architects, develops, and licenses central processing unit products and related technologies for semiconductor companies and original equipment manufacturers rely on to develop products.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Want to dig deeper into these stocks?